Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Pacific Herald.
Press releases published on May 8, 2025

Entrée Resources Announces First Quarter 2025 Results
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) has today filed its interim financial results for the first quarter ended March 31, 2025. All numbers are in U.S. dollars …

ProHance Recognized as a Representative Vendor in Gartner® Market Guide for Task Mining Tools
ProHance recognized as a Representative Vendor by Gartner® for enabling real-time task insights, smarter decisions, and enterprise-wide productivity gains. BENGALURU, KARNATAKA, INDIA, May 8, 2025 /EINPresswire.com/ -- ProHance, a leading workforce …

Pinalalakas ng IUX ang Mga Trader na May Libreng Ekspertong Insight para Mapahusay ang Kasanayan at Kaalaman sa Market
IUX nagbibigay ng libreng ekspertong insight at mga edukasyonal na mapagkukunan upang mapahusay ang kasanayan at kaalaman ng mga trader sa market. LIMASSOL, VINCENT, CYPRUS, May 8, 2025 /EINPresswire.com/ -- Ang IUX, isang nangungunang global trading …

Vital Battery Metals Announces Acquisition of Corvo Uranium Project & Closing of Financing
Highlights: More than 29 km of exploration strike length along three strong NE-SW magnetic low trends coinciding with EM conductors and cross-cutting faults, providing highly prospective shallow drill targets. Uranium mineralization is present along a …

IUX hỗ trợ nhà giao dịch bằng thông tin chuyên sâu miễn phí từ chuyên gia để trau dồi kỹ năng và kiến thức về thị trường
IUX cung cấp thông tin chuyên sâu miễn phí từ chuyên gia và tài nguyên đào tạo để nâng cao kỹ năng giao dịch và kiến thức thị trường cho nhà giao dịch. LIMASSOL, VINCENT, CYPRUS, May 8, 2025 /EINPresswire.com/ -- Nền tảng giao dịch toàn cầu hàng đầu IUX …

Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter …

EnGarde® body armor Partners with TacSource to Expand Distribution in Australia and New Zealand
AMSTERDAM, NH, NETHERLANDS, May 8, 2025 /EINPresswire.com/ -- EnGarde® body armor, a global leader in advanced ballistic protection solutions, is pleased to announce a new partnership with TacSource Group, a premier tactical gear supplier in Australia …

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results …

Global Ship Lease Announces Annual Meeting of Shareholders
ATHENS, Greece, May 08, 2025 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE:GSL) (the “Company”) has scheduled its Annual Meeting of Shareholders for June 17, 2025, at 10:00 a.m. Eastern Time (the “Annual Meeting”). The record date for determining …

Oculis Reports Q1 2025 Financial Results and Provides Company Update
The recent R…

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 …

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal …

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical …

Fulcrum Therapeutics to Participate in Upcoming May Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …

Announcement of IX Asia Index Advisory Committee Member Update
Mr. David Quah and Mr. Manoonrat Lertkomolsuk will join as new member and Mr. CHOW Hin Poon Hugh will retire from Advisory Committee effective 8 May 2025 HONG KONG, HONG KONG, May 8, 2025 /EINPresswire.com/ -- Today, IX Capital International (“IXCI”) …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …